Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?-Reference-Cited by-同舟云学术

Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?

Published:2017-11-21 Issue:6 Volume:5 Page:e00364
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Taneja Amit¹,Vermeulen An²,Huntjens Dymphy R. H.²,Danhof Meindert³,De Lange Elizabeth C. M.³,Proost Johannes H.¹^ORCID

Affiliation:

1. Division of Pharmacokinetics, Toxicology and Targeting; Groningen Research Institute of Pharmacy; University of Groningen; Antonius Deusinglaan 1 9713 AV Groningen The Netherlands

2. Division of Janssen Pharmaceutica NV; Clinical Pharmacology and Pharmacometrics; Janssen Research and Development; Beerse Belgium

3. Department of Pharmacology; Leiden Academic Center for Drug Research; Leiden University; Leiden The Netherlands

Funder

Dutch Top Institute Pharma

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Reference43 articles.

1. Mechanism-based concepts of size and maturity in pharmacokinetics;Anderson;Annu Rev Pharmacol Toxicol,2008

2. Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration;Bagli;J Pharmacol Exp Ther,1999

3. Understanding the behavior of systems pharmacology models using mathematical analysis of differential equations: prolactin modeling as a case study;Bakshi;CPT Pharmacometrics Syst Pharmacol,2016

4. What can we learn from rodents about prolactin in humans?;Ben-Jonathan;Endocr Rev,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons from history predicting a possible tax revolt in South Africa;De Jure;2021

2. Prolactin, flupenthixol decanoate and first episode schizophrenia – clinical and laboratory correlates;Metabolic Brain Disease;2019-08-17

3. The future of drug development: the paradigm shift towards systems therapeutics;Drug Discovery Today;2018-12